Brief: Kaleido Biosciences Inc Announces New Clinical And Preclinical Data Supporting Advancement Of KB295 To A Phase 2 Clinical Study In Mild-To-Moderate Ulcerative Colitis
05/10/2021 12:30
Oct 5 (Reuters) - Kaleido Biosciences Inc KLDO.O :
* KALEIDO BIOSCIENCES ANNOUNCES NEW CLINICAL AND PRECLINICAL
DATA
SUPPORTING ADVANCEMENT OF KB295 TO A PHASE 2 CLINICAL STUDY IN
MILD-TO-MODERATE ULCERATIVE COLITIS
* KALEIDO BIOSCIENCES INC - KB295 REACHED ITS PRIMARY
ENDPOINT
DEMONSTRATING FAVORABLE SAFETY AND TOLERABILITY PROFILE
Source text for Eikon: ID:nGNX4cm8LR
Further company coverage: KLDO.O